title: Human cDNA clones that modify radiomimetic sensitivity of ataxia-telangiectasia (group A) cells.
abstract: Genes responsible for genetic diseases with increased sensitivity to DNA-damaging agents can be identified using complementation cloning. This strategy is based on in vitro complementation of the cellular sensitivity by gene transfer. Ataxia-telangiectasia (A-T) is a multisystem autosomal recessive disorder involving cellular sensitivity to ionizing radiation and radiomimetic drugs. A-T is genetically heterogeneous, with four complementation groups. We attempted to identify cDNA clones that modify the radiomimetic sensitivity of A-T cells assigned to complementation group [A-T(A)]. The cells were transfected with human cDNA libraries cloned in episomal vectors, and various protocols of radiomimetic selection were applied. Thirteen cDNAs rescued from survivor cells were found to confer various degrees of radiomimetic resistance to A-T(A) cells upon repeated introduction, and one of them also partially influenced another feature of the A-T phenotype, radioresistant DNA synthesis. None of the clones mapped to the A-T locus on chromosome 11q22-23. Nine of the clones were derived from known genes, some of which are involved in cellular stress responses. We concluded that a number of different genes, not necessarily associated with A-T, can influence the response of A-T cells to radiomimetic drugs, and hence the complementation cloning approach may be less applicable to A-T than to other diseases involving abnormal processing of DNA damage.
authors.affiliation: Department of Human Genetics, Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel.
authors.forename: Y
authors.initials: Y
authors.lastname: Ziv
authors.forename: A
authors.initials: A
authors.lastname: Bar-Shira
authors.forename: T J
authors.initials: TJ
authors.lastname: Jorgensen
authors.forename: P S
authors.initials: PS
authors.lastname: Russell
authors.forename: A
authors.initials: A
authors.lastname: Sartiel
authors.forename: T B
authors.initials: TB
authors.lastname: Shows
authors.forename: R L
authors.initials: RL
authors.lastname: Eddy
authors.forename: M
authors.initials: M
authors.lastname: Buchwald
authors.forename: R
authors.initials: R
authors.lastname: Legerski
authors.forename: R T
authors.initials: RT
authors.lastname: Schimke
authors.forename: Y
authors.initials: Y
authors.lastname: Shiloh
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D000956:Antigens, Viral / Q000096:biosynthesis / Q000235:genetics; D001260:Ataxia Telangiectasia / Q000235:genetics*; D002461:Cell Line, Transformed; D002470:Cell Survival / Q000187:drug effects* / Q000528:radiation effects*; D002531:Cerebellum / Q000378:metabolism; D002874:Chromosome Mapping; D003001:Cloning, Molecular; D004261:DNA Replication; D018076:DNA, Complementary; D004268:DNA-Binding Proteins / Q000096:biosynthesis / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D019309:Epstein-Barr Virus Nuclear Antigens; D005347:Fibroblasts / Q000378:metabolism; D015723:Gene Library; D005808:Genes, Recessive; D005816:Genetic Complementation Test; D005822:Genetic Vectors; D006367:HeLa Cells; D006801:Humans; D008214:Lymphocytes / Q000378:metabolism; D011401:Promoter Regions, Genetic; D013539:Simian virus 40; D013308:Streptonigrin / Q000494:pharmacology*; D014162:Transfection; D009353:Zinostatin / Q000494:pharmacology*
chemical_list: D000903:Antibiotics, Antineoplastic; D000956:Antigens, Viral; D018076:DNA, Complementary; D004268:DNA-Binding Proteins; D019309:Epstein-Barr Virus Nuclear Antigens; D013308:Streptonigrin; D009353:Zinostatin